Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Memric not associated with liver toxicity, researcher tells Alzheimer's Association.

Executive Summary

SMITHKLINE MEMRIC DOES NOT HAVE LIVER TOXICITY OF TACRINE, RESEARCHER Steven DeKosky, MD, University of Pittsburgh Medical Center, told an Alzheimer's Association meeting in New York City Feb. 5. DeKosky reported that Memric, formerly known as SB 202026, is in Phase III studies. Memric, like Warner-Lambert/Roussel Uclaf's milameline and Lilly's xanomeline, is an M1 receptor agonist, DeKosky observed. "None of these" muscarinic agonists "have the liver toxicity of tacrine" (Warner-Lambert's reversible cholinesterase inhibitor Cognex), he reported.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel